{"id":22452,"date":"2025-07-28T20:54:01","date_gmt":"2025-07-28T07:54:01","guid":{"rendered":"https:\/\/clladvocates.nz\/?page_id=22452"},"modified":"2026-02-23T17:17:15","modified_gmt":"2026-02-23T04:17:15","slug":"pharmac-news","status":"publish","type":"page","link":"https:\/\/clladvocates.nz\/?page_id=22452","title":{"rendered":"Pharmac News"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text uncode_shortcode_id=&#8221;140875&#8243;]<span style=\"color: #333333;\">Pharmac is proposing to fund two fixed\u2011duration combination therapies for people with chronic lymphocytic leukaemia (CLL): venetoclax + ibrutinib and venetoclax + obinutuzumab, both from 1 May 2026.<\/span><\/p>\n<p><span style=\"color: #333333;\">You can read more on this here:\u00a0<\/span><a href=\"https:\/\/clladvocates.nz\/?p=22996\">Funding of Chronic Lymphocytic Leukaemia with Ibrutinib + Venetoclax and Obinutuzumab + Venetoclax<\/a><\/p>\n<p><span style=\"font-family: arial, sans-serif;\"><span style=\"color: #000000;\">These treatments would become available as first\u2011line options for all eligible people with CLL, offering more effective chemotherapy\u2011free regimens and the possibility of longer remission.\u00a0<\/span><\/span><\/p>\n<div><span style=\"color: #000000;\">Pharmac is requesting submissions on its proposal to fund:<\/span><\/div>\n<div><span style=\"color: #000000;\">1. Venetoclax and Ibrutinib<\/span><\/div>\n<div><span style=\"color: #000000;\">2. Venetoclax and Ibrutinib for people who haven&#8217;t previously received treatment for their CLL<\/span><\/div>\n<div><span style=\"color: #000000;\">\u00a0<\/span><\/div>\n<div><span style=\"color: #000000;\">The details of this are on the\u00a0<a href=\"https:\/\/www.pharmac.govt.nz\/news-and-resources\/consultations-and-decisions\/2026-02-proposal-to-fund-two-medicine-combinations-for-chronic-lymphocytic-leukaemia-cll?type=Consultation&amp;page=1&amp;status=open\">Pharmac website<\/a>. People who are partially through either\u00a0of these combinations, having self-funded\u00a0them, will be eligible.\u00a0<\/span><\/div>\n<div><span style=\"color: #000000;\">Otherwise, as the proposal\u00a0stands at the moment, it is only for people who have\u00a0not previously had any previous treatment for their CLL. It is unlikely\u00a0that Pharmac will make major changes to their proposal.\u00a0<\/span><\/div>\n<div><span style=\"color: #000000;\">This is a HUGE step forward and will mean that FRC chemotherapy is unlikely\u00a0to be used very much at all.\u00a0<\/span><\/div>\n<p><span style=\"color: #000000; font-family: arial, sans-serif;\">Consultation is open until 5pm, 4 March 2026,\u00a0and Pharmac is seeking feedback from people with CLL, wh\u0101nau, clinicians, and advocacy groups.<\/span><\/p>\n<p><span style=\"font-family: arial, sans-serif; color: #333333;\">If this proposal affects you or someone you support, please consider making a submission to ensure your voice is heard.<\/span><\/p>\n<p><span style=\"font-family: arial, sans-serif;\"><span style=\"color: #000000;\">Here is the link to submit your feedback:\u00a0<\/span><a href=\"https:\/\/www.pharmac.govt.nz\/news-and-resources\/consultations-and-decisions\/2026-02-proposal-to-fund-two-medicine-combinations-for-chronic-lymphocytic-leukaemia-cll?type=Consultation&amp;page=1&amp;status=open\" target=\"_blank\" rel=\"noopener\">Pharmac Proposal to fund two medicine combinations for chronic lymphocytic leukaemia (CLL)<\/a><\/span>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text uncode_shortcode_id=&#8221;140875&#8243;]Pharmac is proposing to fund two fixed\u2011duration combination therapies for people with chronic lymphocytic leukaemia (CLL): venetoclax + ibrutinib [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":22907,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-22452","page","type-page","status-publish","has-post-thumbnail","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/22452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22452"}],"version-history":[{"count":8,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/22452\/revisions"}],"predecessor-version":[{"id":23015,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/22452\/revisions\/23015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/22907"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}